Why the study?
Does the LPL activator NO-1886 improve cachexia and obesity in animal models?
Does the LPL activator NO-1886 improve cachexia and obesity in animal models?
This preclinical study investigates whether the LPL activator NO-1886 can improve cachexia and obesity in animal models.
Leaves open NO-1886 effects on cachexia or obesity; hypothesis-generating and requires human translation before any clinical consideration.
Cachexia is defined as an extreme wasting condition with marked weight loss. It is observed in paints with cancer and severe infectious disease. Obesity is one of the fasted growing major diseases in developed and developing countries. As has been persuasively argued, long-term imbalance between intake and expenditure of fat is a central factor in the etiology of obesity. We hypothesized that elevating lipoprotein lipase (LPL) activity would cause an improvement of cahexia and obesity. To test this hypothesis, we studied the effects of the LPL activator NO-1886 in cachexia and obese animals.
No takes yet. Share an insight, caveat, or question.
Kusunoki et al. (2013) studied Cachexia and obesity. LPL activator NO-1886 was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: